Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients

Tabone, M.; Laudi, C.; Delmastro, B; Biglino, A; Andreoni, Massimo; F, Chieppa; Bonardi, R; Castaldo, Giuseppe; Cusumano, S; Brunello, F.; Calleri, Guido; Manca, A.; Monica, P. Della; Sidoli, L.; Rizzetto, M.; Pera, A.

doi:10.1016/s0168-8278(01)00166-0

Cited by 31 publications

(40 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AMD had been reported to be effective in treating patients with hepatitis C (23, 24) but confirmation of its effectiveness as monotherapy has proved elusive (25) and a plausible mechanism of action (26) remains to be established. The combination of interferon plus AMD was effective in one trial of 200 patients (14) and in a trial of elderly patients (27), but it was generally ineffective in most clinical trials (15)(16)(17)(18)(19)(20). The combination of interferon plus AMD was also generally ineffective in patients nonresponsive to interferon alone (28)(29)(30)(31) or interferon plus RBV (30).…”

Section: Discussionmentioning

confidence: 99%

“…AMD, which has been used primarily for the prophylaxis and treatment of respiratory tract infections caused by influenza A virus, is believed to prevent the entry of viruses into host cells (12). In patients with chronic HCV infection, the addition of AMD to interferon or interferon plus RBV treatment regimens has shown conflicting results (13)(14)(15)(16)(17)(18)(19)(20).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Peginterferon α-2a Combination Therapies in Chronic Hepatitis C Patients Who Relapsed After or Had a Viral Breakthrough on Therapy with Standard Interferon α-2b Plus Ribavirin: A Pilot Study of Efficacy and Safety

et al. 2005

View full text Add to dashboard Cite

There are no established therapeutic regimens for hepatitis C virus (HCV) patients who relapse following treatment with interferon α-2b and ribavirin or those who break through while on interferon α-2b and ribavirin. We therefore evaluated various combination therapies in HCV patients who relapsed or experienced a viral breakthrough. Patients (n = 124) were randomized to 48 weeks of treatment with once-weekly subcutaneous injections of 180 µg pegylated (peg-) interferon α-2a plus oral ribavirin (800-1000 mg/day), mycophenolate mofetil (2 g/day), amantadine (200 mg/day), or ribavirin and amantadine and followed for an additional 24 weeks. The sustained virologic response was higher in patients administered peginterferon α-2a plus ribavirin (38%) or ribavirin and amantadine (45%) than in those administered peginterferon α-2a plus mycophenolate mofetil (17%) or amantadine (10%). As in previous studies, patients with genotype non-1 and those with lower viral loads had better responses than those with genotype 1 and high viral loads, though the differences did not reach significance. The four treatment regimens had similar safety profiles, except that patients receiving ribavirin had greater maximal hemoglobin decreases. These findings suggest that the combination of peginterferon α-2a plus ribavirin or with ribavirin and amantadine is effective in some HCV patients who relapse after treatment with interferon α-2b plus ribavirin.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Peginterferon α-2a Combination Therapies in Chronic Hepatitis C Patients Who Relapsed After or Had a Viral Breakthrough on Therapy with Standard Interferon α-2b Plus Ribavirin: A Pilot Study of Efficacy and Safety

et al. 2005

View full text Add to dashboard Cite

show abstract

“…[24][25][26][27][28] Main observations of our large, double-blind, randomized, placebo-controlled trial in treatment-naive patients with chronic hepatitis are: (1) amantadine increased sustained virologic response numerically, but statistically not significantly (by ϳ 7%); (2) amantadine significantly reduced virologic breakthrough (by ϳ 10%); (3) in multivariate logistic regression analysis, amantadine treatment just reached the level of significance (P ϭ .05) as independent predictor of sustained virologic response; (4) treatment with amantadine was safe and well tolerated; (5) the cost-effective- Fig. 2.…”

Section: Discussionmentioning

confidence: 99%

Interferon and amantadine in naive chronic hepatitis C: A double-blind, randomized, placebo-controlled trial

Helbling

Stamenic

Viani³

et al. 2002

Hepatology

View full text Add to dashboard Cite

Recent controlled trials on the efficacy of an amantadine/interferon combination in treatment-naive patients with chronic hepatitis C yielded contradictory results. We therefore conducted a large, double-blind, placebo-controlled, multicenter trial in naive patients with chronic hepatitis C: 246 patients were randomized to receive interferon alfa-2a (6 MIU sc thrice weekly for 20 weeks, then 3 MIU sc thrice weekly) and either amantadine sulphate (2 ؋ 100 mg po QD) or placebo. Treatment continued for a total of 52 weeks, if HCV-RNA in serum polymerase chain reaction (PCR) had fallen below detection limit (1,000 copies/ mL) at treatment week 10, and stopped otherwise. All patients were followed for 24 weeks off therapy.

show abstract

“…Three centres in Italy, and one each in the United Kingdom, Germany, and Switzerland agreed to make their databases available. Five of the six RCTs have been published as full papers [3][4][5][6][7], whereas preliminary results from Di Marco's study have been presented [9]. From the Caronia study [4], only data from the multicentre trial were evaluated.…”

Section: Methodsmentioning

confidence: 99%

Combination therapy with amantadine and interferon in naı̈ve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials

Mangia

Leandro

Helbling

et al. 2004

Journal of Hepatology

Self Cite

View full text Add to dashboard Cite

Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients

Cited by 31 publications

References 16 publications

Peginterferon α-2a Combination Therapies in Chronic Hepatitis C Patients Who Relapsed After or Had a Viral Breakthrough on Therapy with Standard Interferon α-2b Plus Ribavirin: A Pilot Study of Efficacy and Safety

Peginterferon α-2a Combination Therapies in Chronic Hepatitis C Patients Who Relapsed After or Had a Viral Breakthrough on Therapy with Standard Interferon α-2b Plus Ribavirin: A Pilot Study of Efficacy and Safety

Interferon and amantadine in naive chronic hepatitis C: A double-blind, randomized, placebo-controlled trial

Combination therapy with amantadine and interferon in naı̈ve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials

Contact Info

Product

Resources

About